Search results
Results from the WOW.Com Content Network
During the COVID-19 pandemic, antagonistic antibodies against the IL-6 receptors were tested in clinical trials to assess their use in treating or preventing severe pneumonia in critically ill COVID-19 patients. Such antibodies include tocilizumab and sarilumab. [18] [19] [20] Antibodies against IL-6 itself, such as siltuximab, were also ...
It contains nogapendekin alfa, a human IL-15N72D variant; [2] [3] and inbakicept, an interleukin 15 receptor subunit alpha. [ 4 ] [ 5 ] The most common adverse reactions include increased creatinine, dysuria, hematuria, urinary frequency, micturition urgency, urinary tract infection, increased potassium, musculoskeletal pain, chills, and pyrexia.
This list of over 500 monoclonal antibodies includes approved and investigational drugs as well as drugs that have been withdrawn from market; consequently, the column Use does not necessarily indicate clinical usage. See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page.
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Immune stimulating antibody conjugates work by activating dendritic cells within the tumor, [3] and are capable of being delivered systemically. [4] With some patients being resistant to checkpoint inhibitors , immune stimulating antibody conjugates may be able to harness an immune response generated through the stimulation of toll-like ...
Efti – as a soluble LAG-3 protein – is an MHC class II agonist and therefore a dendritic-cell activator, causing increased antigen presentation to cytotoxic (CD8+) T cells. In the absence of antigen presentation via MHC class II molecules, efti reactivates dormant antigen-experienced memory T cells , allowing them to recognize their antigen ...
Ixekizumab binds to interleukin 17 (IL-17A), a pro-inflammatory cytokine, and blocks its action. Among other things, IL-17A stimulates proliferation and activation of keratinocytes in the skin. [10] This mechanism is similar to that of another anti-psoriasis antibody, brodalumab, which binds to the interleukin-17 receptor. [19]
Guselkumab lowers the release of immune system signalling molecules, increasing the risk of infections from bacteria, viruses, and fungi. [7]The most common side effects for guselkumab are upper respiratory tract infections, headache, injection site reactions, [10] joint pain, diarrhea, gastroenteritis, fungal skin infections and herpes simplex infections.